Method for diagnosis of sepsis by determination of S100B

• US 20050064506A1
• Filed: 11/27/2002
• Published: 03/24/2005
• Est. Priority Date: 12/04/2001
• Status: Active Grant

• Current Assignee: B·R·A·H·M·S GmbH (Thermo Fisher Scientific Incorporated)
• Original Assignee: B.R.A.H.M.S Aktiengesellschaft
• Inventors: Bergmann, Andreas
• Granted Patent: US 7,569,209 B2
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: G01N 2800/26 Infectious diseases, e.g. generalised sepsis
• CPC Class Codes: G01N 33/56911 Bacteria
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Method for early differential diagnosis and detection, for prognosis and for assessing the severity and for therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections, in which, preferably with determination of at least one further parameter suitable for sepsis diagnosis, the amount of S100B in a biological fluid of a patient in whom a sepsis is present or sepsis is suspected is determined and conclusions with regard to the presence, the expected course, the severity and/or the success of initiated measures for the therapy of sepsis are drawn from the determined amount of S100B.

Claims

1. Method for early differential diagnosis and detection, for prognosis and for assessing the severity or for therapy-accompanying assessment of the course of sepsis or sepsis-like systemic infections, comprising testing a biological fluid of a human patient in whom sepsis is present or sepsis is suspected for the presence and/or amount of the parameter S100B, wherein the presence and/or amount of the parameter S100B is indicative of the presence, the expected cause, the severity and/or the success of initiated measures for the therapy of the sepsis.

2. Method according to claim 1, wherein said biological fluid is human serum.

3. Method according to claim 1, wherein said sepsis is a bacterial sepsis.

4. Method according to claim 1, wherein the presence and/or amount of the parameter S100B is determined by an immunodiagnostic assay method.

5. Method according to claim 1, wherein said method is carried out in the course of a multiparameter determination in which at least one further sepsis parameter is simultaneously determined and a measured result in the form of a set of at least two measured variables is obtained and is evaluated for fine sepsis diagnosis.

6. Method according to claim 5, wherein said at least one further sepsis parameter determined in the course of the multiparameter determination is selected from the group consisting of procalcitonin, CA 19-9, CA 125, S100A proteins, soluble cytokeratin fragments, CYFRA 21, TPS, soluble cytokeratin-1 fragments (sCYIF), Inflammin, CHP, peptide prohormones and the C-reactive protein (CRP).

7. Method according to claim 5, wherein said multiparameter determination is carried out as a simultaneous determination using a chip technology measuring apparatus or an immunochromatographic measuring apparatus.

8. Method according to claim 7, wherein said measuring apparatus provides a complex measured result and wherein the evaluation of said complex measured result is carried out using a computer program.

9. Method according to claim 5, wherein said method is carried out in the course of a multiparameter determination in which further sepsis parameters are simultaneously determined and a measured result in the form of a set of measured variables is obtained and is evaluated for fine sepsis diagnosis.